{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T17:07:00Z","timestamp":1758820020920,"version":"3.37.3"},"reference-count":58,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2010,6,1]]},"DOI":"10.1185\/03007991003745209","type":"journal-article","created":{"date-parts":[[2010,4,8]],"date-time":"2010-04-08T13:57:29Z","timestamp":1270735049000},"page":"1363-1375","source":"Crossref","is-referenced-by-count":32,"title":["Current therapy for Lambert\u2013Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment"],"prefix":"10.1185","volume":"26","author":[{"given":"A.","family":"Quartel","sequence":"first","affiliation":[{"name":"BioMarin Europe Ltd, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Turbeville","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc., Novato, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Lounsbury","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc., Novato, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2010,4,8]]},"reference":[{"key":"CIT0001","unstructured":"Orphanet: Lambert\u2013Eaton myasthenic syndrome. Available at: http:\/\/www.orpha.net [Last accessed 22 January 2010]"},{"key":"CIT0002","first-page":"612","volume":"187","author":"Lambert EH","year":"1956","journal-title":"Am J Physiol"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.10.1323"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-8467(02)00054-9"},{"key":"CIT0005","first-page":"577","volume":"111","author":"O\u2019Neill JH","year":"1988","journal-title":"A review of 50 cases. Brain"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)76153-5"},{"key":"CIT0007","unstructured":"Elias A. Pathobiology and staging of small cell carcinoma of the lung. UpToDate. Available at: http:\/\/www.uptodate.com\/online\/content\/topic.do?topicKey=lung_ca\/5407&selectedTitle=1%7E150&source=search_result [Last accessed 22 January 2010]"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01266.x"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01476.x"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.3.678"},{"key":"CIT0011","unstructured":"Commission of the European Communities. Commission decision of 18\/12\/2002 relating to the designation of medicinal product \u20183,4-diaminopyridine phosphate\u2019 as an orphan medicinal product. Brussels: C(2002)5445, 2002"},{"key":"CIT0012","unstructured":"Committee for medicinal products for human use. Committee for medicinal products for human use summary of positive opinion for ZENAS, International Nonproprietary Name (INN): amifampridine. London: EMEA\/CHMP\/655953\/2009, 2009"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.75.887.516"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.73.6.766"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1378\/chest.91.5.716"},{"key":"CIT0016","unstructured":"Orphanet: Myasthenia gravis. Available at: http:\/\/www.orpha.net [Last accessed 22 January 2010]"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.58.1.85"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(96)05303-8"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.65.2.213"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.05.025"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2004.10.018"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.5133"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.2298\/MPNS0510495Z"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.12.111"},{"key":"CIT0025","doi-asserted-by":"crossref","unstructured":"Pelayo Alvarez M, Gallego Rubio O, Bonfill Cosp X, et al. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev 2009;CD001990","DOI":"10.1002\/14651858.CD001990.pub2"},{"key":"CIT0026","unstructured":"Kelly K. First-line chemotherapy for small cell lung cancer. UpToDate. Available at: http:\/\/www.uptodate.com\/online\/content\/topic.do?topicKey=lung_ca\/6976&selectedTitle=2%7E150&source=search_result [Last accessed 22 January 2010]"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1038\/317737a0"},{"key":"CIT0028","first-page":"682","volume":"102","author":"Peterlin BL","year":"2002","journal-title":"J Am Osteopath Assoc"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21315"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21301"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2008.03.006"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.35"},{"key":"CIT0033","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0022-3565(25)22023-7","volume":"227","author":"Thomsen RH","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.31.3.265"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.10.1324"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(80)90378-7"},{"key":"CIT0037","doi-asserted-by":"crossref","unstructured":"Maddison P, Newsom-Davis J. Treatment for Lambert\u2013Eaton myasthenic syndrome. Cochrane Database Syst Rev 2005;CD003279","DOI":"10.1002\/14651858.CD003279.pub2"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(84)90875-8"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.46.7.684"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198912073212303"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.3.603"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1993.tb22949.x"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21422"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.47.9.1052"},{"key":"CIT0045","doi-asserted-by":"crossref","unstructured":"Flet L, Polard E, Guillard O, et al. 3,4-Diaminopyridine safety in clinical practice: an observational, retrospective cohort study. J Neurol 2010;doi:10.1007\/s00415-009-5442-6","DOI":"10.1007\/s00415-009-5442-6"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1007\/s004150170262"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.3109\/15563659509017992"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1993.tb04205.x"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199912)22:12<1727::AID-MUS19>3.0.CO;2-K"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000339380.23073.58"},{"key":"CIT0051","doi-asserted-by":"crossref","unstructured":"Schwam E. Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. J Emerg Med 2009: published online 12 May 2009, doi:10.1016\/j.jemermed.2009.04.037","DOI":"10.1016\/j.jemermed.2009.04.037"},{"key":"CIT0052","unstructured":"Limited FDA survey of compounded drug products. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2003. Available at: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/PharmacyCompounding\/ucm155725.htm [Last accessed 22 January 2010]"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2006.06.007"},{"key":"CIT0054","unstructured":"Common technical document Zenas\u00ae 10\u2009mg, scored tablets \u2013 3,4-DAP phosphate (INN: amifampridine). Module 2.4. Non-clinical overview"},{"key":"CIT0055","unstructured":"Common technical document Zenas\u00ae 10\u2009mg, scored tablets \u2013 3,4-DAP phosphate (INN: amifampridine). Module 2.5. Clinical overview"},{"key":"CIT0056","unstructured":"Funck-Bretano C. Relative bioavailability study of 3,4-DAP administered as a salt or a base. DAPSEL study. Clinical study report. February 2006"},{"key":"CIT0057","unstructured":"Common technical document Zenas\u00ae 10\u2009mg, scored tablets \u2013 3,4-DAP phosphate (INN: amifampridine). Module 5.3.5.4.3. Prospective collection of safety data from patients treated with 3,4-diaminopyridine under French ATU program"},{"key":"CIT0058","unstructured":"Warning letter sent by AFSSaPS to health professionals on December 11th 2006"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/03007991003745209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T22:09:47Z","timestamp":1740002987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/03007991003745209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,8]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6,1]]}},"alternative-id":["10.1185\/03007991003745209"],"URL":"https:\/\/doi.org\/10.1185\/03007991003745209","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"type":"print","value":"0300-7995"},{"type":"electronic","value":"1473-4877"}],"subject":[],"published":{"date-parts":[[2010,4,8]]}}}